Anti-IL-2 Receptor Antibodies versus Anti-Thymocyte Globulin for Induction Therapy in Kidney Transplantation

被引：7
作者：
Mandelbrot, Didier [1 ]
机构：
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Transplant Inst, Boston, MA 02215 USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2009年 / 20卷 / 06期
关键词：
RABBIT ANTITHYMOCYTE GLOBULIN; RENAL-ALLOGRAFT RECIPIENTS; CONTAINING TRIPLE THERAPY; ACUTE CELLULAR REJECTION; MYCOPHENOLATE-MOFETIL; BASILIXIMAB INDUCTION; MONOCLONAL-ANTIBODY; IMMUNOPROPHYLAXIS; EFFICACY;
D O I：
10.1681/ASN.2009040389
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1170 / 1171
页数：2
相关论文
共 13 条
  • [1] Long-term results of rabbit antithymocyte globulin and basiliximab induction
    Brennan, Daniel C.
    Schnitzler, Mark A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (16) : 1736 - 1738
  • [2] Rabbit antithymocyte globulin versus basiliximab in renal transplantation
    Brennan, Daniel C.
    Daller, John A.
    Lake, Kathleen D.
    Cibrik, Diane
    Del Castillo, Domingo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (19) : 1967 - 1977
  • [3] Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody
    Kahan, BD
    Rajagopalan, PR
    Hall, M
    [J]. TRANSPLANTATION, 1999, 67 (02) : 276 - 284
  • [4] Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression:: Efficacy and safety
    Kyllonen, Lauri E.
    Eklund, Bjorn H.
    Pesonen, Eero J.
    Salmela, Kaija T.
    [J]. TRANSPLANTATION, 2007, 84 (01) : 75 - 82
  • [5] Randomized double-blind study of immunoprophylaxis with basiliekimab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation
    Lawen, JG
    Davies, EA
    Mourad, G
    Oppenheimer, F
    Molina, MG
    Rostaing, L
    Wilkinson, AH
    Mulloy, LL
    Bourbigot, BJ
    Prestele, H
    Korn, A
    Girault, D
    [J]. TRANSPLANTATION, 2003, 75 (01) : 37 - 43
  • [6] Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy
    Lebranchu, Y
    Bridoux, F
    Büchler, M
    Le Meur, Y
    Etienne, I
    Toupance, O
    de Ligny, BH
    Touchard, G
    Moulin, B
    Le Pogamp, P
    Reigneau, O
    Guignard, M
    Rifle, G
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2002, 2 (01) : 48 - 56
  • [7] Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era
    Meier-Kriesche, HU
    Schold, JD
    Srinivas, TR
    Kaplan, B
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (03) : 378 - 383
  • [8] Sequential protocols using basiliximab versus anti-thymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids
    Mourad, G
    Rostaing, L
    Legendre, C
    Garrigue, V
    Thervet, E
    Durand, D
    [J]. TRANSPLANTATION, 2004, 78 (04) : 584 - 590
  • [9] Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
    Nashan, B
    Moore, R
    Amlot, P
    Schmidt, AG
    Abeywickrama, K
    Soulillou, JP
    [J]. LANCET, 1997, 350 (9086) : 1193 - 1198
  • [10] Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients
    Noel, Christian
    Abramowicz, Daniel
    Durand, Dominique
    Mourad, Georges
    Lang, Philippe
    Kessler, Michele
    Charpentier, Bernard
    Touchard, Guy
    Berthoux, Francois
    Merville, Pierre
    Ouali, Nacera
    Squifflet, Jean-Paul
    Bayle, Francois
    Wissing, Karl Martin
    Hazzan, Marc
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (06): : 1385 - 1392
12